Research and Markets: Merck Generics Had Sales of Just Under 1.8 Billion Euros in 2005.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c37923) has announced the addition of the "Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: Merck Generics Company Intelligence Report" to their offering. Our generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA ANDA abbr. abbreviated new drug application approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . Topics Covered * Products * Financial Results * Merck Generics Generic Companies Analysis Merck Generics is a subsidiary division of Merck KGaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. based in Darmstadt, Germany. It has no connection with the US-based Merck & Co. With sales of just under 1.8 billion euros in 2005, generics now form the largest segment of Merck KGaA's pharmaceutical business, accounting for 46% of revenues. Merck's generic businesses are not grouped under a single name. The leading subsidiaries are Alphapharm, the leading generic manufacturer in Australia, and Merck Generiques, based in France. Other important subsidiaries include Genpharm, in Canada, and Generics (UK). Genpharm opened a US office in 2005. Strong rumours have emerged in the German press regarding a possible sale of Merck's generic businesses. The company has confirmed this is a possibility, but no decision has yet been made. The Merck Serono In September 2006, Merck KGaA announced its intent to purchase the majority of Serono shares from Ernesto Bertarelli and the Bertarelli family. The Merck-Serono merger was announced on September 21, 2006. Merck KGaA and Serono operated as distinct entities until at least January 2007. board expects to decide the unit's future in the first half of 2007. The latest generic acquisition for Merck is Prasfarma, a former subsidiary of Almirall Prodesfarma This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. based in Barcelona, Spain. The 20 million euro deal was completed in early 2006. In 2004, Merck moved its leading US Company, Dey, into its generic division, as 'the basis for strategic reorientation'. Dey is not a generic manufacturer as such, but develops novel delivery systems for off-patent products. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion